A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters

The emergence of SARS-CoV-2 variants of concern (VOC) requires adequate coverage of vaccine protection. We evaluated whether a spike ferritin nanoparticle vaccine (SpFN), adjuvanted with the Army Liposomal Formulation QS21 (ALFQ), conferred protection against the B.1.1.7 and B.1.351 VOCs in Syrian g...

Descripción completa

Detalles Bibliográficos
Autores principales: Wuertz, Kathryn McGuckin, Barkei, Erica K., Chen, Wei-Hung, Martinez, Elizabeth J., Lakhal-Naouar, Ines, Jagodzinski, Linda L., Paquin-Proulx, Dominic, Gromowski, Gregory D., Swafford, Isabella, Ganesh, Akshaya, Dong, Ming, Zeng, Xiankun, Thomas, Paul V., Sankhala, Rajeshwer S., Hajduczki, Agnes, Peterson, Caroline E., Kuklis, Caitlin, Soman, Sandrine, Wieczorek, Lindsay, Zemil, Michelle, Anderson, Alexander, Darden, Janice, Hernandez, Heather, Grove, Hannah, Dussupt, Vincent, Hack, Holly, de la Barrera, Rafael, Zarling, Stasya, Wood, James F., Froude, Jeffrey W., Gagne, Matthew, Henry, Amy R., Mokhtari, Elham Bayat, Mudvari, Prakriti, Krebs, Shelly J., Pekosz, Andrew S., Currier, Jeffrey R., Kar, Swagata, Porto, Maciel, Winn, Adrienne, Radzyminski, Kamil, Lewis, Mark G., Vasan, Sandhya, Suthar, Mehul, Polonis, Victoria R., Matyas, Gary R., Boritz, Eli A., Douek, Daniel C., Seder, Robert A., Daye, Sharon P., Rao, Mangala, Peel, Sheila A., Joyce, M. Gordon, Bolton, Diane L., Michael, Nelson L., Modjarrad, Kayvon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219092/
https://www.ncbi.nlm.nih.gov/pubmed/34159328
http://dx.doi.org/10.1101/2021.06.16.448525
Descripción
Sumario:The emergence of SARS-CoV-2 variants of concern (VOC) requires adequate coverage of vaccine protection. We evaluated whether a spike ferritin nanoparticle vaccine (SpFN), adjuvanted with the Army Liposomal Formulation QS21 (ALFQ), conferred protection against the B.1.1.7 and B.1.351 VOCs in Syrian golden hamsters. SpFN-ALFQ was administered as either single or double-vaccination (0 and 4 week) regimens, using a high (10 μg) or low (0.2 μg) immunogen dose. Animals were intranasally challenged at week 11. Binding antibody responses were comparable between high- and low-dose groups. Neutralizing antibody titers were equivalent against WA1, B.1.1.7, and B.1.351 variants following two high dose two vaccinations. SpFN-ALFQ vaccination protected against SARS-CoV-2-induced disease and viral replication following intranasal B.1.1.7 or B.1.351 challenge, as evidenced by reduced weight loss, lung pathology, and lung and nasal turbinate viral burden. These data support the development of SpFN-ALFQ as a broadly protective, next-generation SARS-CoV-2 vaccine.

Ejemplares similares